ArticleMicrobiology spectrum2022
Coexistence of
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 24 citations in OpenAlex.
- Phenotypic and genomic characterization of tigecycline-insensitiveMicrobiology spectrum · 2026Article
- Characterization of tmexCD-toprJ-positive Klebsiella spp. from pediatric patients in a Chinese hospital.BMC microbiology · 2026Article
- Characterization of multidrug-resistant ST978-KL103Microbiology spectrum · 2026Article
- Epidemiological and genomic profiles of NDM-1-Producing ST25-KL2 carbapenem-resistant Klebsiella pneumoniae among pediatric patients in Hangzhou, China.BMC microbiology · 2026Article
- Assembly and inhibition of transferable TMexCD1-TOprJ1 efflux pump.Nature communications · 2025Article
- Emergence of Tigecycline-Nonsusceptible Carbapenem-ResistantPathogens (Basel, Switzerland) · 2025Article
- Genomic characteristics of ST6115 carbapenem-resistantFrontiers in microbiology · 2025Article
- Coexistence of plasmid-mediatedMicrobiology spectrum · 2024Article
- Coexistence of blaAnnals of clinical microbiology and antimicrobials · 2024Article
- Mobile Tigecycline Resistance: An Emerging Health Catastrophe Requiring Urgent One Health Global Intervention.Frontiers in microbiology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In clinical practice, carbapenems and tigecycline are considered significant options for treating infections caused by multidrug-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.